Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

Please provide your email address to receive an email when new articles are posted on . RNA therapeutics lowered all-cause mortality, increased 6-minute walk distance and improved quality of life. RNA ...

RNA interference (RNAi) therapy offers groundbreaking potential to revolutionize disease treatment by targeting gene silencing. Opportunities lie in developing alternative treatments for conditions ...

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) gains attention across Nasdaq index fund holdings after upgrade and strong quarterly performance.

Biogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies targeting serious diseases. Under the agreement, City Therapeutics will use its ...

Late last week, the FDA approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (12 years of age and older) with ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the treatment of cancer associated with this oncogenic variant. Researchers at the ...